Summary of medicine characteristics - Chanhold
SUMMARY OF PRODUCT CHARACTERISTICS
-
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Chanhold 15 mg spot-on solution for cats and dogs < 2.5 kg
Chanhold 30 mg spot-on solution for dogs 2.6–5.0 kg
Chanhold 45 mg spot-on solution for cats 2.6–7.5 kg
Chanhold 60 mg spot-on solution for cats 7.6–10.0 kg
Chanhold 60 mg spot-on solution for dogs 5.1–10.0 kg
Chanhold 120 mg spot-on solution for dogs 10.1–20.0 kg
Chanhold 240 mg spot-on solution for dogs 20.1–40.0 kg
Chanhold 360 mg spot-on solution for dogs 40.1–60.0 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single-dose (pipette) delivers:
Active substance:
Chanhold 15 mg for cats and dogs
6% w/v solution 12% w/v solution 6% w/v solution 6% w/v solution 12% w/v solution 12% w/v solution 12% w/v solution 12% w/v solution
Selamectin 120 mg
Selamectin 240 mg
Selamectin 360 mg
Chanhold 30 mg for dogs
Chanhold 45 mg for cats
Chanhold 60 mg for cats
Chanhold 60 mg for dogs
Chanhold 120 mg for dogs
Chanhold 240 mg for dogs
Chanhold 360 mg for dogs
Excipients:
Butylated hydroxytoluene (E321) 0.08%.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Spot-on solution.
Clear colourless to yellow solution.
4. CLINICAL PARTICULARS4.1 Target species
Dogs and cats.
-
4.2 Indications for use, specifying the target species
Cats and dogs:
- • Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.
- • Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration.
The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.
- • Treatment of ear mites (Otodectes cynotis).
Cats:
- • Treatment of biting lice infestations (Felicola subrostratus)
- • Treatment of adult roundworms (Toxocara cati)
- • Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Dogs:
- • Treatment of biting lice infestations (Trichodectes canis)
- • Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
- • Treatment of adult intestinal roundworms (Toxocara canis).
4.3 Contraindications
Do not use in animals under 6 weeks of age.
Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
-
4.4 Special warnings for each target species
Animals may be bathed 2 hours after treatment without loss of efficacy.
Do not apply when the animal’s hair coat is wet. However, shampooing or soaking the animal 2 or more hours after treatment will not reduce the efficacy of the product.
For ear mite treatment, do not apply directly to the ear canal.
It is important to apply the dose as indicated to minimise the quantity that the animal can lick off. If significant licking does occur, a brief period of hypersalivation may rarely be observed in cats.
-
4.5 Special precautions for use
Special precautions for use in animals
This veterinary medicinal product is to be applied to the skin surface only. Do not administer orally or parenterally.
Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
This product is highly flammable; keep away from heat, sparks, open flames or other sources of ignition.
The product is a skin and eye irritant.
Do not smoke, eat or drink while handling the product.
Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and seek medical advice immediately and show the package leaflet or the label to the physician.
Avoid direct contact with treated animals until the application site is dry. On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children. Used applicators should be disposed of immediately and not left within the sight or reach of children.
People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the product with caution.
Other precautions
Do not allow treated animals to bathe in water courses until at least two hours after treatment administration.
-
4.6 Adverse reactions (frequency and seriousness)
Use of the veterinary medicinal product in cats has on rare occasions been associated with a mild transient alopecia at the site of application. On very rare occasions transient focal irritation may also be observed. The alopecia and irritation are normally self-resolving, but symptomatic therapy may be applicable in some circumstances.
If significant licking occurs, a brief period of hypersalivation may rarely be observed in cats.
On rare occasions in cats and dogs, application of the veterinary medicinal product may produce a local temporary clumping of the hair at the application site and/or an occasional appearance of a small quantity of a white powder. This is normal and will disappear typically within 24 hours of treatment administration and does not affect either the safety or efficacy of the veterinary medicinal product.
Very rarely, as with other macrocyclic lactones, reversible neurological signs, including seizures, have been observed after use of the veterinary medicinal product in both dogs and cats.
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-
– common (more than 1 but less than 10 animals in 100 animals treated)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
-
4.7 Use during pregnancy, lactation or lay
The product can be used in breeding, pregnant and lactating cats and dogs.
4.8 Interaction with other medicinal products and other forms of interaction
None known.
-
4.9 Amounts to be administered and administration route
The product should be administered as a single application of a single dose delivering a minimum of 6 mg/kg selamectin. When concurrent infestations or infections in the same animal are to be treated with the veterinary medicinal product, only one application of the recommended 6 mg/kg dose should be administered at any one time. The appropriate length of the treatment period for individual parasites is specified below.
Administer in accordance with the following table:
| Cats (kg) | Product | mg of selamectin dispensed | Potency (mg/ml) | nominal pipette size, ml |
| < 2.5 | 1 pipette of Chanhold 15 mg for cats and dogs < 2.5 kg | 15 | 60 | 0.25 |
| 2.6–7.5 | 1 pipette of Chanhold 45 mg for cats 2.6–7.5 kg | 45 | 60 | 0.75 |
| 7.6–10.0 | 1 pipette of Chanhold 60 mg for cats 7.6–10 kg | 60 | 60 | 1.0 |
| >10 | Appropriate combination of pipettes | 60 | Appropriate combination of pipettes |
| Dogs (kg) | Product | mg of selamectin dispensed | Potency (mg/ml) | nominal pipette size, ml |
| < 2.5 | 1 pipette of Chanhold 15 mg for cats and dogs < 2.5 kg | 15 | 60 | 0.25 |
| 2.6–5.0 | 1 pipette of Chanhold 30 mg for dogs 2.6–5.0 kg | 30 | 120 | 0.25 |
| 5.1–10.0 | 1 pipette of Chanhold 60 mg for dogs 5.1–10.0 kg | 60 | 120 | 0.5 |
| 10.1–20.0 | 1 pipette of Chanhold 120 mg for dogs 10.1–20.0 kg | 120 | 120 | 1.0 |
| 20.1–40.0 | 1 pipette of Chanhold 240 mg for dogs 20.1–40.0 kg | 240 | 120 | 2.0 |
| 40.1–60.0 | 1 pipette of Chanhold 360 mg for dogs 40.1–60.0 kg | 360 | 120 | 3.0 |
| > 60 | Appropriate combination of pipettes | 60/120 | Appropriate combination of pipettes |
Flea treatment and prevention (cats and dogs)
Following administration of the veterinary medicinal product, the adult fleas on the animal are killed, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.
For the prevention of flea infestations, the veterinary medicinal product should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.
For use as part of a treatment strategy for flea allergy dermatitis the veterinary medicinal product should be administered at monthly intervals.
Prevention of heartworm disease (cats and dogs)
The veterinary medicinal product may be administered year-round or at least within one month of the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of the veterinary medicinal product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms. When replacing another heartworm preventive veterinary medicinal product in a heartworm disease prevention programme, the first dose of the veterinary medicinal product must be given within a month of the last dose of the former medication.
Treatment of roundworm infections (cats and dogs)
A single dose of the veterinary medicinal product should be administered.
Treatment of biting lice (cats and dogs)
A single dose of the veterinary medicinal product should be administered.
Treatment of ear mites (cats)
A single dose of the veterinary medicinal product should be administered.
Treatment of ear mites (dogs)
A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at the time of treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Treatment of hookworm infections (cats)
A single dose of the veterinary medicinal product should be administered.
Treatment of sarcoptic mange (dogs)
For complete elimination of the mites, a single dose of the veterinary medicinal product should be administered for two consecutive months.
Method of administration:
Remove the product pipette from its protective package.
Hold the pipette upright.
Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Snap back the tip.
Part the animal’s coat at the base of the neck in front of the shoulder blades until the skin is visible.
Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot.
Apply to the skin at the base of the neck in front of the shoulder blades.
Avoid contact between the product and your fingers.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No undesirable effects were observed after the administration of 10 times the recommended dose. Selamectin was administered at 3 times the recommended dose to cats and dogs infected with adult heartworms and no undesirable effects were observed. Selamectin was also administered at 3 times the recommended dose to breeding male and female cats and dogs, including pregnant and lactating females nursing their litters and at 5 times the recommended dose to ivermectin-sensitive Collies, and no undesirable effects were observed.
-
4.11 Withdrawal period(s)
Not applicable.
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: antiparasitic products, insecticides and repellents, macrocyclic lactones. ATCvet code: QP54AA05.
5.1 Pharmacodynamic properties
Selamectin is a semi-synthetic compound of the avermectin class. Selamectin paralyses and/or kills a wide range of invertebrate parasites through interference with their chloride channel conductance causing disruption of normal neurotransmission. This inhibits the electrical activity of nerve cells in nematodes and muscle cells in arthropods leading to their paralysis and/or death.
Selamectin has adulticidal, ovicidal and larvicidal activity against fleas. Therefore, it effectively breaks the flea life cycle by killing adults (on the animal), preventing the hatching of eggs (on the animal and in its environment) and by killing larvae (environment only). Debris from selamectin- treated pets kills flea eggs and larvae not previously exposed to selamectin and thus may aid in the control of existing environmental flea infestations in areas to which the animal has access.
Activity has also been demonstrated against heartworm larvae.
-
5.2 Pharmacokinetic particulars
Following spot on administration selamectin is absorbed from the skin reaching maximum plasma concentrations approximately 1 and 3 days after administration in cats and dogs respectively. Following absorption from the skin selamectin distributes systemically and is slowly eliminated from plasma as manifested in detectable plasma concentrations in dogs and cats 30 days after administration of a single topical dose at 6 mg/kg. The prolonged persistence and slow elimination of selamectin from plasma is reflected in the terminal elimination half-life values of 8 and 11 days in cats and dogs respectively. The systemic persistence of selamectin in plasma and the lack of extensive metabolism provide effective concentrations of selamectin for the duration of the inter-dosing interval (30 days).
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
Butylated hydroxytoluene (E321)
Dipropylene glycol methyl ether
Isopropyl alcohol
6.2 Major incompatibilities
Not applicable.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
6.4. Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
-
6.5 Nature and composition of immediate packaging
The veterinary medicinal product is presented in a white plastic pipette formed from a layer of polypropylene/cyclic olefin copolymer/polypropylene with a layer of polyethylene/ethylene vinyl alcohol/polyethylene.
The product is available in packs of three pipettes (all strengths), six pipettes (all strengths except 15 mg), or fifteen pipettes (15 mg strength only) in individual foil sachets within an outer carton.
Not all pack sizes may be marketed.
-
6.6 Special precautions for the disposal of unused veterinary medicinal product or
waste
materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
The product should not enter water courses as this may be dangerous for fish and other aquatic organisms. Containers and residual contents should be disposed of along with collected domestic refuse to avoid contamination of any water courses.
7. MARKETING AUTHORISATION HOLDER
Chanelle Pharmaceuticals Manufacturing Ltd,
Loughrea,
Co. Galway,
Ireland
8. MARKETING AUTHORISATION NUMBER(S)
EU/2/19/236/001–016
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 17/04/2019